Duration: 2021 - 2024
Preparing for RSV Immunisation and Surveillance in Europe. The initiative will advance knowledge on RSV to better inform vaccination policies and drug development.
Duration: 2021 - 2024
The objective of PROMISE (Preparing for RSV Immunisation and Surveillance in Europe), an IMI (Innovative Medicines Initiative) project is taking a major leap forward in the fight against Respiratory Syncytial Virus (RSV) in Europe and worldwide. In addition, the project will evaluate the impact of COVID-19 on RSV epidemiology with a special focus on older adults.
RSV is associated with substantial disease burden in young children and the elderly. Globally, an estimated 33 million young children are diagnosed with RSV each year, with over 3 million cases requiring hospitalisation. RSV accounts for hospitalisation of 1 in 5 young children <5 years diagnosed with acute lower respiratory infections (ALRI) and 1 in 6 in adults > 65 years. Annually, the virus causes an estimated 118,000 child deaths worldwide. RSV costs governments around the world nearly 5 billion euros every year.
Focus on long-term impact
The PROMISE initiative builds on RESCEU’s (Respiratory Syncytial Virus Consortium in Europe) achievements, another IMI-funded project focused on generating insights into the impact of RSV on healthcare systems and society and creating a biorepository to assist future research.
PROMISE will considerably advance scientific knowledge on RSV to better inform public health strategies and to support the development and monitoring of novel immunisation and therapeutics against this potentially deadly virus in the paediatric and elderly populations. At present, four potential vaccines and a monoclonal antibody to protect against this virus are in Phase III clinical studies, whilst another 15 products are under clinical development.
PROMISE aims to decrease this burden by:
- enhancing the value proposition for RSV immunisation by generating new insights on RSV and addressing current gaps, such as understanding the relationship between RSV infection and school age wheeze and asthma
- identifying new diagnostic tools and prophylactic interventions
- adding knowledge on RSV biomarkers
To achieve our aims, we will develop a robust surveillance network on RSV disease, that aims to strengthen epidemiological and virological surveillance in Europe, share this data among public health institutes and disclose surveillance data to the community. This will contribute to widening knowledge on respiratory infections in the community and guide therapeutics in the long term. More detailed information can be found on the project website imi-promise.eu
Translational scientists, clinicians, public health agencies, the pharmaceutical industry, patient groups and clinical societies will work together within the PROMISE Consortium. The group represents 22 organisations with a track-record on RSV research:
The University of Edinburgh (United Kingdom); Universitair Medisch Centrum Utrecht (Netherlands); Universiteit Antwerpen (Belgium); Imperial College of Science, Technology and Medicine (United Kingdom); The Chancellor, Masters and Scholars of the University of Oxford (United Kingdom); Terveyden Ja Hyvinvoinnin Laitos (Finland); Rijksinstituut voor Volksgezondheid en Milieu (Netherlands); Nivel, Nederlands Instituut voor Onderzoek van de Gezondheidzorg (Netherlands); Varsinais-Suomen Sairaanhoitopiirin Kuntayhtymä (Finland); TEAM IT Research, S.L. (Spain); Stichting Resvinet (Netherlands); Statens Serum Institut (Denmark); Servizo Galego de Saúde (Spain); Fondazione PENTA - For the treatment and care of children with HIV and related diseases - ONLUS (Italy); Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (Spain); Martin-Luther-Universitaet Halle-Wittenberg (Germany); Sanofi Pasteur, S.A. (France); GlaxoSmithKline Biologicals, S.A. (Belgium); Janssen Pharmaceutica, N.V (Belgium); Novavax Inc. (United States); Pfizer Limited (United Kingdom); Astrazeneca AB (Sweden).
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 101034339. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Nivel project team
The Nivel project team consists of:
- John Paget PhD, senior researcher (epidemiologist) Disasters and Environmental Hazards
- Jojanneke van Summeren MSc, researcher Disasters and Environmental Hazards and General Practice Care
- Prof. Michel Dückers PhD, coordinator research program Disasters and Environmental Hazards
Want to know more? Contact us!
For more information on this project you can visit our project website imi-promise.eu. Please feel free to get in touch with the Nivel expert(s) involved. You will find them on the right, together with the (future) publications and other relevant content. We look forward to getting in touch with you!